Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Issue 8 (4th February 2005)

• Record Type: Journal Article
• Authors: Vander Cruyssen, B; Hoffman, I E A; Zmierczak, H; Van den Berghe, M; Kruithof, E; De Rycke, L; Mielants, H; Veys, E M; Baeten, D; De Keyser, F
• Is Part Of: Annals of the rheumatic diseases. Volume 64:Issue 8(2005)
• Page Start: 1145
• Page End: 1149
• Publication Date: 2005-02-04
• Subjects: ACPA, anti-citrullinated protein/peptide antibodies -- CCP, cyclic citrullinated peptide -- DIP, distal interphalangeal joint -- ESSG, European Spondyloarthropathy Study Group -- pepA, peptide A -- pepB, peptide B -- RF, rheumatoid factor -- RXJC, radiological joint count -- SJC, swollen joint count; anti-CCP -- psoriatic arthritis; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2004.032177
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are considered highly specific markers of rheumatoid arthritis. Despite the high specificity of the test, anti-CCP antibodies have also been observed in psoriatic arthritis. Objective: To determine the frequency of anti-CCP antibodies in psoriatic arthritis and to describe the clinical characteristics of such patients. Methods: Serum samples from 192 patients with psoriatic arthritis were analysed for anti-CCP antibodies. A previously defined cut off point was applied at a specificity level of ⩾98.5% (42 U/ml). Antibodies against pepA and pepB (two synthetic citrullinated peptides) were determined on samples containing anti-CCP antibodies by line immune assay. The swollen joint count and the numbers of affected joints (present or past) were recorded. Clinical features were noted and if available radiographs of hands and feet were scored for erosions. Rheumatoid factor was determined in all samples. Results: Anti-CCP antibodies were found in 15 patients (7.8%); 13 of 15 anti-CCP2 positive samples were also positive for anti-pepA or pepB antibodies. The prevalence of anti-CCP antibodies was higher than expected in view of the highly specific cut off applied in the test. Detailed analysis of the clinical and radiological features makes it improbable that the high prevalence of anti-CCP antibodies resulted solely from concomitant psoriasis and rheumatoid arthritis or from misclassification. Conclusions: Anti-CCP antibodies may be present in patients with psoriatic arthritis. Although some of the present cohort could have had psoriasis with concomitant rheumatoid arthritis, a proportion at least had the typical characteristics of psoriatic arthritis as the primary diagnosis.